STERIS (NYSE:STE) Releases Quarterly Earnings Results

STERIS (NYSE:STE) announced its quarterly earnings results on Monday. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03), FiscalAI reports. STERIS had a return on equity of 14.23% and a net margin of 13.18%.The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the company earned $2.74 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. STERIS updated its FY 2027 guidance to 11.100-11.300 EPS.

STERIS Stock Down 0.2%

Shares of STE stock traded down $0.32 on Wednesday, hitting $210.53. 346,826 shares of the stock were exchanged, compared to its average volume of 780,225. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $20.65 billion, a P/E ratio of 26.57 and a beta of 0.95. The business has a 50-day moving average of $221.54 and a 200 day moving average of $243.52. STERIS has a fifty-two week low of $195.14 and a fifty-two week high of $269.44.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio is currently 31.78%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on STE shares. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. KeyCorp lowered their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $271.40.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.07% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of STE. State Street Corp boosted its position in STERIS by 6.0% during the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after purchasing an additional 260,001 shares during the last quarter. Orbis Allan Gray Ltd boosted its position in STERIS by 5.6% during the fourth quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock valued at $570,296,000 after purchasing an additional 120,200 shares during the last quarter. AQR Capital Management LLC boosted its position in STERIS by 37.2% during the fourth quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock valued at $411,522,000 after purchasing an additional 440,164 shares during the last quarter. Janus Henderson Group PLC boosted its position in STERIS by 0.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,482,635 shares of the medical equipment provider’s stock valued at $375,879,000 after purchasing an additional 13,175 shares during the last quarter. Finally, Invesco Ltd. boosted its position in STERIS by 10.2% during the fourth quarter. Invesco Ltd. now owns 1,410,612 shares of the medical equipment provider’s stock valued at $357,618,000 after purchasing an additional 130,470 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.